Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 96

1.

Mutational analysis of cutaneous squamous cell carcinomas and verrucal keratosis in patients taking BRAF inhibitors.

Anforth R, Tembe V, Blumetti T, Fernandez-Peñas P.

Pigment Cell Melanoma Res. 2012 Sep;25(5):569-72. doi: 10.1111/j.1755-148X.2012.01031.x. Epub 2012 Aug 6.

PMID:
22726224
2.

Systemic retinoids for the chemoprevention of cutaneous squamous cell carcinoma and verrucal keratosis in a cohort of patients on BRAF inhibitors.

Anforth R, Blumetti TC, Clements A, Kefford R, Long GV, Fernandez-Peñas P.

Br J Dermatol. 2013 Dec;169(6):1310-3. doi: 10.1111/bjd.12519.

PMID:
23870055
3.

Induction of cutaneous squamous cell carcinomas by RAF inhibitors: cause for concern?

Lacouture ME, O'Reilly K, Rosen N, Solit DB.

J Clin Oncol. 2012 Jan 20;30(3):329-30. doi: 10.1200/JCO.2011.38.2895. Epub 2011 Nov 7. No abstract available.

PMID:
22067405
4.

Mechanisms of BRAFi-induced hyperproliferative cutaneous conditions.

Ali M, Anforth R, Senetiner F, Carlos G, Fernandez-Penas P.

Exp Dermatol. 2016 May;25(5):394-5. doi: 10.1111/exd.12975. No abstract available.

PMID:
26896751
5.

RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors.

Oberholzer PA, Kee D, Dziunycz P, Sucker A, Kamsukom N, Jones R, Roden C, Chalk CJ, Ardlie K, Palescandolo E, Piris A, MacConaill LE, Robert C, Hofbauer GF, McArthur GA, Schadendorf D, Garraway LA.

J Clin Oncol. 2012 Jan 20;30(3):316-21. doi: 10.1200/JCO.2011.36.7680. Epub 2011 Nov 7.

6.

COX-2 inhibition prevents the appearance of cutaneous squamous cell carcinomas accelerated by BRAF inhibitors.

Escuin-Ordinas H, Atefi M, Fu Y, Cass A, Ng C, Huang RR, Yashar S, Comin-Anduix B, Avramis E, Cochran AJ, Marais R, Lo RS, Graeber TG, Herschman HR, Ribas A.

Mol Oncol. 2014 Mar;8(2):250-60. doi: 10.1016/j.molonc.2013.11.005. Epub 2013 Dec 1.

7.

Factors influencing the development of cutaneous squamous cell carcinoma in patients on BRAF inhibitor therapy.

Anforth R, Menzies A, Byth K, Carlos G, Chou S, Sharma R, Scolyer RA, Kefford R, Long GV, Fernandez-Peñas P.

J Am Acad Dermatol. 2015 May;72(5):809-15.e1. doi: 10.1016/j.jaad.2015.01.018. Epub 2015 Mar 3.

PMID:
25748298
8.

BRAF and RKIP are significantly decreased in cutaneous squamous cell carcinoma.

Zaravinos A, Kanellou P, Baritaki S, Bonavida B, Spandidos DA.

Cell Cycle. 2009 May 1;8(9):1402-8. Epub 2009 May 26.

PMID:
19342899
9.

Merkel cell polyomavirus and human papilloma virus in proliferative skin lesions arising in patients treated with BRAF inhibitors.

Falchook GS, Rady P, Konopinski JC, Busaidy N, Hess K, Hymes S, Nguyen HP, Prieto VG, Bustinza-Linares E, Lin Q, Parkhurst KL, Hong DS, Sherman S, Tyring SK, Kurzrock R.

Arch Dermatol Res. 2016 Jul;308(5):357-65. doi: 10.1007/s00403-016-1650-y. Epub 2016 Apr 20.

PMID:
27098388
11.

The occurrence of non-melanoma malignant skin lesions and non-cutaneous squamous-cell carcinoma among metastatic melanoma patients: an observational cohort study in Denmark.

Li H, Pedersen L, Nørgaard M, Ulrichsen SP, Thygesen SK, Nelson JJ.

BMC Cancer. 2016 May 3;16:295. doi: 10.1186/s12885-016-2315-0.

12.

Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma.

Long GV, Menzies AM, Nagrial AM, Haydu LE, Hamilton AL, Mann GJ, Hughes TM, Thompson JF, Scolyer RA, Kefford RF.

J Clin Oncol. 2011 Apr 1;29(10):1239-46. doi: 10.1200/JCO.2010.32.4327. Epub 2011 Feb 22.

PMID:
21343559
13.

Squamoproliferative lesions arising in the setting of BRAF inhibition.

Harvey NT, Millward M, Wood BA.

Am J Dermatopathol. 2012 Dec;34(8):822-6. doi: 10.1097/DAD.0b013e3182604873.

PMID:
22771896
14.

Prevalence of human papillomavirus DNA in cutaneous neoplasms from renal allograft recipients supports a possible viral role in tumour promotion.

Stark LA, Arends MJ, McLaren KM, Benton EC, Shahidullah H, Hunter JA, Bird CC.

Br J Cancer. 1994 Feb;69(2):222-9.

15.

Is it good or bad to find a BRAF mutation?

Flaherty KT.

J Clin Oncol. 2011 Apr 1;29(10):1229-30. doi: 10.1200/JCO.2010.34.0497. Epub 2011 Feb 22. No abstract available.

PMID:
21343552
16.

RAF inhibition and induction of cutaneous squamous cell carcinoma.

Robert C, Arnault JP, Mateus C.

Curr Opin Oncol. 2011 Mar;23(2):177-82. doi: 10.1097/CCO.0b013e3283436e8c. Review.

PMID:
21192261
17.

Comparative profiles of BRAF inhibitors: the paradox index as a predictor of clinical toxicity.

Adelmann CH, Ching G, Du L, Saporito RC, Bansal V, Pence LJ, Liang R, Lee W, Tsai KY.

Oncotarget. 2016 May 24;7(21):30453-60. doi: 10.18632/oncotarget.8351.

18.

Detection of BRAF gene mutation in primary choroidal melanoma tissue.

Malaponte G, Libra M, Gangemi P, Bevelacqua V, Mangano K, D'Amico F, Mazzarino MC, Stivala F, McCubrey JA, Travali S.

Cancer Biol Ther. 2006 Feb;5(2):225-7. Epub 2006 Feb 20.

PMID:
16410717
19.

Cutaneous manifestations of dabrafenib (GSK2118436): a selective inhibitor of mutant BRAF in patients with metastatic melanoma.

Anforth RM, Blumetti TC, Kefford RF, Sharma R, Scolyer RA, Kossard S, Long GV, Fernandez-Peñas P.

Br J Dermatol. 2012 Nov;167(5):1153-60. doi: 10.1111/j.1365-2133.2012.11155.x. Epub 2012 Oct 5.

PMID:
22804352
20.

Targeting BRAFV600E in thyroid carcinoma: therapeutic implications.

Mitsiades CS, Negri J, McMullan C, McMillin DW, Sozopoulos E, Fanourakis G, Voutsinas G, Tseleni-Balafouta S, Poulaki V, Batt D, Mitsiades N.

Mol Cancer Ther. 2007 Mar;6(3):1070-8.

Supplemental Content

Support Center